team grant : hiv cure research
eligibility criteria for all cihr research funding programs apply. the business office of the institution of an eligible nominated principal applicant generally administers cihr funds. refer to the individual eligibility requirements regarding the eligibility requirements for individuals and institutions.
eligibility to apply
for your application to be eligible:
- the nominated principal applicant must be an independent researcher appointed at an eligible institution (see institutional eligibility requirements for eligibility process and associated timelines).
- at least two team members (i.e., co-principal applicants and/or co-applicants), other than the nominated principal applicant, must also be independent researchers.
- a. at least one team member must be an independent researcher who is also a health professional engaged in clinical hiv care.
- b. at least one team member must be a new investigator. a new investigator is defined as a researcher who has held a full time research appointment (e.g., faculty appointment providing eligibility to apply for grants and/or supervise trainees), for a period of 0 to 60 months as of the full application deadline.
- the team must include individuals (listed as principal applicants and/or co-applicants) from at least two unaffiliated research institutions.
in addition to the mandatory eligibility requirements listed above, teams are encouraged to:
- include international collaborators;
- include investigators whose primary area of research is not hiv, and whose expertise will help accomplish the goals of the research program;
- involve industrial partners to enable translational research and facilitate the application of findings into commercial applications;
- involve other knowledge users and/or partners;
- include a governance plan which outlines the oversight of the research program in terms of scientific conduct and priorities, administration and ensuring the relevance of the research to people living with hiv.
this funding opportunity includes a registration deadline (may 24, 2013) and a full application deadline (june 26, 2013). full applications are due in the office of research services two weeks prior to the external deadline.
the overall goal of this initiative is to contribute to the global search for a safe and effective cure for hiv.
the specific objectives of this funding opportunity are to:
- transform hiv cure research in canada into a collaborative, interdisciplinary model of knowledge creation and application through the funding of research programs that actively engage hiv basic scientists and clinical investigators as well as experts from complimentary disciplines and sectors;
- increase knowledge of hiv latency and persistence in areas that are not well covered by other research teams in canada or internationally;
- effectively translate knowledge into clinical and/or commercial applications which contribute to the design, development and evaluation of curative strategies;
- provide a high-quality training and mentoring environment; and,
- create a critical mass of technical and scientific expertise in canada that engages meaningfully with one another, relevant national stakeholders and international research efforts.
relevant research areas
the cihr hiv/aids research initiative will provide funding for applications that are determined to be relevant to the following seven priorities for hiv cure research, as identified in the towards an hiv cure global scientific strategy. these priority areas are fully described in the full recommendations posted on the ias website. (note: access the full recommendations document by clicking on the link in the upper right hand side of the page.) it is not expected that programs will address all of the priority areas listed below, but rather, that they will target one or more of the priority areas.
- cellular and viral mechanisms that maintain hiv persistence;
- tissues and cellular sources of persistent hiv/siv in animal models and in long-term art-treated individuals;
- origins of immune activation and dysfunction in the presence of art and their consequences for hiv/siv persistence;
- host and immune mechanisms that control hiv/siv infection but allow viral persistence;
- assays to study and measure persistent infection comparison and validation;
- therapeutic agents or immunological strategies to safely eliminate latent infection in individuals on art;
- strategies to enhance the capacity of the host response to control active viral replication.